Imagine a lock that doesn't just open or close, but can be turned in several different ways to trigger different actions. Current drug tests are like using ten different clumsy tools to guess how the lock is turning, which often leads to mistakes. This technology uses special glowing sensors that act like a high-definition camera, showing exactly how the lock moves in one single test.
Pharmaceutical companies waste significant resources on drug failures because current GPCR assays provide misleading readouts. They must run over 10 different tests in different contexts to understand a drug's effect.
A single-assay platform consisting of functionalized fluorophore reagents (SensArrs) and a high-sensitivity tri-scanning confocal microscope.
If you are a drug discovery enterprise dealing with costly drug failure due to misleading readouts from 10+ distinct assays — this project developed a single-assay technology platform that provides superior confidence in functional classification of drug candidates.
If you are an AI-driven drug design SME dealing with a lack of high-quality training data for receptor conformations — this project developed a platform with the capacity to efficiently harness artificial intelligence to design better drugs.
If you are a biosensor manufacturer dealing with low sensitivity in fluorescence detection — this project developed a novel tri-scanning confocal microscope that substantially increases detection sensitivity.
Based on available project data, pricing information is not provided as the project is currently in the proof-of-principle stage.
The project aims to create a standard tool for early drug development, though current work focuses on demonstrating that conformational fingerprints correlate to signaling profiles.
Based on available project data, specific licensing terms are not mentioned, but the project is coordinated by ISAR BIOSCIENCE GmbH, an SME.
It replaces the need for 10+ distinct assays with a single-assay platform that works from the test tube to native disease-relevant cells.
The project period runs from 2023-11-01 to 2027-10-31, indicating it is still in the development phase.
The consortium is highly balanced for commercialization, featuring a 50% industry ratio with 4 SMEs and 4 other partners. The collaboration spans 6 countries (CH, CZ, DE, ES, FR, NL), combining the agility of small biotechs with the research depth of 2 universities and 2 research institutes, led by a German SME.
Contact ISAR BIOSCIENCE GmbH in Germany
Contact us to track the transition of UniSens from proof-of-principle to industrial pilot.
